^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TRS005

    i
    Associations

    News

    Trials
    Company:
    Zhejiang Teruisi Biopharma
    Drug class:
    Microtubule inhibitor, CD20-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    1m
    A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL. (clinicaltrials.gov)
    P2, N=139, Not yet recruiting, Zhejiang Teruisi Pharmaceutical Inc.
    New P2 trial
    |
    TRS005
    2years
    A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (clinicaltrials.gov)
    P1, N=152, Recruiting, Zhejiang Teruisi Pharmaceutical Inc. | Trial completion date: Nov 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    TRS005
    almost3years
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive NHL. (clinicaltrials.gov)
    P1, N=121, Recruiting, Zhejiang Teruisi Pharmaceutical Inc.
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    TRS005